Citations 2
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky, Kevin, Barlow, William E., Gralow, Julie R., Meric-Bernstam, Funda, Albain, Kathy S., Hayes, Daniel F., Lin, Nancy U., Perez, Edith A., Goldstein, Lori J., Chia, Stephen K.L., Dhesy-Thind, Sukhbinder, Rastogi, Priya, Alba, Emilio, Delaloge, Suzette, Kelly, Catherine M., Ruiz-Borrego, Manuel, Gil-Gil, Miguel, Arce-Salinas, Claudia H., Brain, Etienne G.C., Lee, Eun-Sook, Pierga, Jean-Yves, Bermejo, Begoña, Ramos-Vazquez, Manuel, Jung, Kyung-Hae, Ferrero, Jean-Marc, Schott, Anne F., Shak, Steven, Sharma, Priyanka, Lew, Danika L., Miao, Jieling, Tripathy, Debasish, Pusztai, Lajos, Alba, Emilio , Tripathy, Debu , Kelly, Catherine M. , Dhesy‐Thind, Sukhbinder , Martin, Miguel , Hortobagyi, Gabriel N , Tripathy, Debasish , Dhesy-Thind, Sukhbinder , Alba, Emilio , Kalinsky, Kevin, Barlow, William E., Gralow, Julie R., Meric-Bernstam, Funda, Albain, Kathy S., Hayes, Daniel F., Lin, Nancy U., Perez, Edith A., Goldstein, Lori J., Chia, Stephen K.L., Rastogi, Priya, Delaloge, Suzette, Kelly, Catherine M., Ruiz-Borrego, Manuel, Gil-Gil, Miguel, Arce-Salinas, Claudia H., Brain, Etienne G.C., Lee, Eun-Sook, Pierga, Jean-Yves, Bermejo, Begoña, Ramos-Vazquez, Manuel, Jung, Kyung-Hae, Ferrero, Jean-Marc, Schott, Anne F., Shak, Steven, Sharma, Priyanka, Lew, Danika L., Miao, Jieling, Pusztai, Lajos
New England Journal of Medicine | December 1, 2021 | Volume: 385 | Issue: 25 | Pages: 2336-2347
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Jain, Apurva , Kelley, Robin Kate , Wáng, Ying , Baggerly, Keith, Al‐Shamsi, Humaid O. , Ahn, Daniel H. , DeLeon, Thomas, Bocobo, Andrea Grace, Bekaii‐Saab, Tanios , Shroff, Rachna T. , Javle, Milind , Abdel-Wahab, Reham, Meric-Bernstam, Funda, Baggerly, Keith A, Kaseb, Ahmed Omar, Al-Shamsi, Humaid O, Bekaii-Saab, Tanios S , Borad, Mitesh J. , Abdel‐Wahab, Reham , Meric‐Bernstam, Funda , Kaseb, Ahmed O , Al-Shamsi, Humaid O
JCO Precision Oncology | January 17, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-12
Purpose FGFR genetic aberrations (GAs) occur in an estimated 10% to 16% of intrahepatic cholangiocarcinomas (CCAs). The natural history of CCA with FGFR GAs, the prognostic role of coexisting GAs, and the outcome with FGFR-targeted inhibitors are unknown. Patients and Methods Patients with CCA with FGFR GAs were identified using next-generation sequencing or fluorescence in situ hybridization from four tertiary cancer centers and compared with FGFR wild-type counterparts. Data reviewed included demographic, treatment, overall survival (OS), and GA data. Fisher’s exact test, Kaplan-Meier plots, and log-rank tests were used for statistical analysis. Results Three hundred seventy-seven patients with CCA were identified, and 95 had FGFR GAs. FGFR2 GA was most common (n = 74, with 63 fusions) and seen in intrahepatic CCA. In patients with CCA, FGFR GAs occurred more frequently in younger patients (≤ 40 years; 20%) compared with older patients (> 40 years; 6.7%; P < .001), presented at an earlier stage (TNM stage I/II v III/IV: 35.8% v 22%, respectively; P = .001), and were associated with a longer OS compared with patients without FGFR GAs (37 v 20 months, respectively; P < .001). This difference remained significant after excluding 36 patients treated with FGFR inhibitors. There was no OS difference ( P = .60) between CCA with FGFR2 fusions (n = 63) versus other FGFR GAs (n = 29). Patients with FGFR GAs had a better OS with FGFR-targeted therapy compared with standard treatment ( P = .01). BAP1 mutation was the most common coexisting mutation without prognostic impact, whereas TP53 ( P = .04) and CDKN2A/B ( P = .04) were correlated with a shorter OS. Conclusion CCA with FGFR GAs represents a unique subtype occurring in younger patients with an indolent disease course. FGFR-targeted therapy may have a positive impact on OS in this subgroup.